Therapeutic Monoclonal Antibodies against Cancer: Present and Future
A series of monoclonal antibodies with therapeutic potential against cancer have been generated and developed. Ninety-one are currently used in the clinics, either alone or in combination with chemotherapeutic agents or other antibodies, including immune checkpoint antibodies. These advances helped...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/24/2837 |
| _version_ | 1797381659825274880 |
|---|---|
| author | Marisa Delgado Jose A. Garcia-Sanz |
| author_facet | Marisa Delgado Jose A. Garcia-Sanz |
| author_sort | Marisa Delgado |
| collection | DOAJ |
| description | A series of monoclonal antibodies with therapeutic potential against cancer have been generated and developed. Ninety-one are currently used in the clinics, either alone or in combination with chemotherapeutic agents or other antibodies, including immune checkpoint antibodies. These advances helped to coin the term personalized medicine or precision medicine. However, it seems evident that in addition to the current work on the analysis of mechanisms to overcome drug resistance, the use of different classes of antibodies (IgA, IgE, or IgM) instead of IgG, the engineering of the Ig molecules to increase their half-life, the acquisition of additional effector functions, or the advantages associated with the use of agonistic antibodies, to allow a broad prospective usage of precision medicine successfully, a strategy change is required. Here, we discuss our view on how these strategic changes should be implemented and consider their pros and cons using therapeutic antibodies against cancer as a model. The same strategy can be applied to therapeutic antibodies against other diseases, such as infectious or autoimmune diseases. |
| first_indexed | 2024-03-08T20:54:37Z |
| format | Article |
| id | doaj.art-494b34eae74a4f4bbfe9e9d047ae329c |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-08T20:54:37Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-494b34eae74a4f4bbfe9e9d047ae329c2023-12-22T13:59:44ZengMDPI AGCells2073-44092023-12-011224283710.3390/cells12242837Therapeutic Monoclonal Antibodies against Cancer: Present and FutureMarisa Delgado0Jose A. Garcia-Sanz1Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), 28040 Madrid, SpainDepartment of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), 28040 Madrid, SpainA series of monoclonal antibodies with therapeutic potential against cancer have been generated and developed. Ninety-one are currently used in the clinics, either alone or in combination with chemotherapeutic agents or other antibodies, including immune checkpoint antibodies. These advances helped to coin the term personalized medicine or precision medicine. However, it seems evident that in addition to the current work on the analysis of mechanisms to overcome drug resistance, the use of different classes of antibodies (IgA, IgE, or IgM) instead of IgG, the engineering of the Ig molecules to increase their half-life, the acquisition of additional effector functions, or the advantages associated with the use of agonistic antibodies, to allow a broad prospective usage of precision medicine successfully, a strategy change is required. Here, we discuss our view on how these strategic changes should be implemented and consider their pros and cons using therapeutic antibodies against cancer as a model. The same strategy can be applied to therapeutic antibodies against other diseases, such as infectious or autoimmune diseases.https://www.mdpi.com/2073-4409/12/24/2837therapeutic antibodiescancer treatmenttransmembrane proteinsbioinformaticscancer database analyses |
| spellingShingle | Marisa Delgado Jose A. Garcia-Sanz Therapeutic Monoclonal Antibodies against Cancer: Present and Future Cells therapeutic antibodies cancer treatment transmembrane proteins bioinformatics cancer database analyses |
| title | Therapeutic Monoclonal Antibodies against Cancer: Present and Future |
| title_full | Therapeutic Monoclonal Antibodies against Cancer: Present and Future |
| title_fullStr | Therapeutic Monoclonal Antibodies against Cancer: Present and Future |
| title_full_unstemmed | Therapeutic Monoclonal Antibodies against Cancer: Present and Future |
| title_short | Therapeutic Monoclonal Antibodies against Cancer: Present and Future |
| title_sort | therapeutic monoclonal antibodies against cancer present and future |
| topic | therapeutic antibodies cancer treatment transmembrane proteins bioinformatics cancer database analyses |
| url | https://www.mdpi.com/2073-4409/12/24/2837 |
| work_keys_str_mv | AT marisadelgado therapeuticmonoclonalantibodiesagainstcancerpresentandfuture AT joseagarciasanz therapeuticmonoclonalantibodiesagainstcancerpresentandfuture |